The Impact of Nucleotide Sequence Analysis on Meningococcal Vaccine Development and Assessment

被引:3
|
作者
Maiden, Martin Christopher James [1 ]
机构
[1] Univ Oxford, Dept Zool, Oxford, England
来源
FRONTIERS IN IMMUNOLOGY | 2019年 / 9卷
基金
英国惠康基金; 美国国家卫生研究院;
关键词
Neisseria meningitidis; conjugate polysaccharide vaccines; outer membrane vesicle vaccines; population biology; herd immunity; efficacy; OUTER-MEMBRANE PROTEIN; HORIZONTAL GENETIC EXCHANGE; AFRICAN MENINGITIS BELT; NEISSERIA-MENINGITIDIS; SEROGROUP-B; CONJUGATE VACCINE; STRAIN COVERAGE; CARRIAGE; DISEASE; POPULATION;
D O I
10.3389/fimmu.2018.03151
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Since it became available as a routine tool in biology, the determination and analysis of nucleotide sequences has been applied to the design of vaccines and the investigation of their effectiveness. As vaccination is primarily concerned with the interaction of biological molecules with the immune system, the utility of sequence data is not immediately obvious and, indeed, nucleotide sequence data are most effective when used to complement more conventional immunological approaches. Here, the impact of sequencing on the field of vaccinology will be illustrated with reference to the development and implementation of vaccines against Neisseria meningitidis (the meningococcus) over the 30-year period from the late-1980s to the late-2010s. Nucleotide sequence-based studies have been important in the fight against this aggressive pathogen largely because of its high genetic and antigenic diversity, properties that were only fully appreciated because of sequence-based studies. Five aspects will be considered, the use of sequence data to: (i) discover vaccine antigens; (ii) assess the diversity and distribution of vaccine antigens; (iii) determine the evolutionary and population biology of the organism and their implications for immunization; and (iv) develop molecular approaches to investigate pre- and post-vaccine pathogen populations to assess vaccine impact. One of the great advantages of nucleotide sequence data has been its scalability, which has meant that increasingly large data sets have been available, which has proved invaluable in the investigation of an organism as diverse and enigmatic as the meningococcus.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] DEVELOPMENT OF A MENINGOCOCCAL VACCINE
    POOLMAN, JT
    INFECTIOUS AGENTS AND DISEASE-REVIEWS ISSUES AND COMMENTARY, 1995, 4 (01): : 13 - 28
  • [2] CHOLERA-TOXIN GENES - NUCLEOTIDE-SEQUENCE, DELETION ANALYSIS AND VACCINE DEVELOPMENT
    MEKALANOS, JJ
    SWARTZ, DJ
    PEARSON, GDN
    HARFORD, N
    GROYNE, F
    DEWILDE, M
    NATURE, 1983, 306 (5943) : 551 - 557
  • [3] Impact of Meningococcal B Vaccine on Invasive Meningococcal Disease in Adolescents
    McMillan, Mark
    Wang, Bing
    Koehler, Ann P.
    Sullivan, Thomas R.
    Marshall, Helen S.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (01) : E233 - E237
  • [4] Special Focus: Meningococcal Vaccine Development
    Ellis, Ronald
    Riedmann, Eva M.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (07) : 845 - 845
  • [5] Meningococcal vaccine in pregnancy: An assessment of infant risk
    Letson, GW
    Little, JR
    Ottman, J
    Miller, GL
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (03) : 261 - 263
  • [6] Long-Term Impact of Meningococcal Vaccine
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (04) : 691 - 691
  • [7] Impact of serogroup A meningococcal conjugate vaccine for Africa
    Stuart, James M.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (05) : 1116 - 1117
  • [8] Impact of meningococcal C conjugate vaccine in the UK
    Balmer, P
    Borrow, R
    Miller, E
    JOURNAL OF MEDICAL MICROBIOLOGY, 2002, 51 (09) : 717 - 722
  • [9] NUCLEOTIDE-SEQUENCE ANALYSIS OF URABE MUMPS VACCINE STRAIN THAT CAUSED MENINGITIS IN VACCINE RECIPIENTS
    BROWN, EG
    FURESZ, J
    DIMOCK, K
    YAROSH, W
    CONTRERAS, G
    VACCINE, 1991, 9 (11) : 840 - 842
  • [10] Analysis of novel meningococcal vaccine formulations
    Zughaier, Susu M.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (07) : 1728 - 1732